1.Goh, KT. The national childhood immunization programmes in Singapore. Singapore Medical Journal 1985; 26: 225–242.
2.Goh, KT. Epidemiological Surveillance of Communicable Diseases in Singapore. Tokyo: Southeast Asian Medical Information Center, 1983, pp. 170–200.
3.Ahmad, MT, et al. Rubella in male Singapore adolescents: incidence and effects of vaccination. Singapore Medical Journal 1984;25: 404–407.
4.Committee on Epidemic Diseases, Singapore. Introduction of measles-mumps-rubella (MMR) vaccine into the national childhood immunization programme. Epidemiological News Bulletin 1989; 15: 66–68.
5.Committee on Epidemic Diseases, Singapore. Progress in the elimination of measles from Singapore. Epidemiological News Bulletin 2003; 29: 1–5.
6.Liew, F, et al. Evaluation on the effectiveness of the national childhood immunization programme in Singapore, 1982–2007. Annals Academy of Medicine Singapore 2010; 39: 532–541.
7.Ministry of Health, Singapore. Communicable Diseases Surveillance in Singapore 2010. Singapore: Ministry of Health, 2011, pp. 119–129.
8.Committee on Epidemic Diseases, Singapore. Seroepidemiology of measles, mumps and rubella in Singapore. Epidemiological News Bulletin 1991; 17: 25–26.
9.Committee on Epidemic Diseases, Singapore. Prevalence of antibodies to measles, mumps and rubella in Singapore. Epidemiological News Bulletin 1995; 21: 25–29.
10.Committee on Epidemic Diseases, Singapore. Serosurveillance of rubella in Singapore. Epidemiological News Bulletin 2001; 27: 1–3.
11.Ang, LW. Seroepidemiology of rubella in Singapore, 2004. Epidemiological News Bulletin 2008; 34: 67–69.
12.Ministry of Health, Singapore. National Health Survey 2004, Singapore. Epidemiology and Disease Control Division, 2005.
13.Wilson, EB. Probable inference, the law of succession, and statistical inference. Journal of the American Statistical Association 1927; 22: 209–212.
14.Armitage, P, Berry, G, Matthews, JNS. Statistical Methods in Medical Research, 4th edn.Oxford: Blackwell Science, 2002, pp. 662–663.
15.Fine, PE. Herd immunity: history, theory, practice. Epidemiologic Reviews 1993; 15: 265–302.
16.Uzicanin, A, Zimmerman, L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. Journal of Infectious Diseases 2011; 204 (Suppl. 1): S133–148.
17.Andrews, N, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bulletin of the World Health Organization 2008;86: 197–204.
18.Robert, W, et al. National Serosurvey of Vaccine Preventable Diseases. Wellington, New Zealand: Ministry of Health, 2009.
19.Rager-Zisman, B, et al. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clinical and Diagnostic Laboratory Immunology 2004; 11: 913–918.
20.Poland, GA, et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999; 17: 1525–1531.
21.Committee on Epidemic Diseases, Singapore. Prevalence of antibodies to measles in Singapore. Epidemiological News Bulletin 2000; 26: 10–11.
22.Chen, CJ, et al. Waning population immunity to measles in Taiwan. Vaccine. Published online: 23 May 2012. doi:10.1016/j.vaccine.2012.05.019.
26.Goh, KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet 1999; 354: 1355–1356.
27.Akehurst, C. Resurgence of mumps in Singapore associated with Rubini vaccine. Eurosurveillance 1999; 3: 1312.
28.Committee on Epidemic Diseases, Singapore. Surveillance of mumps in Singapore, 1998. Epidemiological News Bulletin 1999; 25: 27–29.
29.Kutty, PK, et al. Seroprevalence of antibody to mumps virus in the US population, 1999–2004. Journal of Infectious Diseases 2010; 202: 667–674.
32.Ong, G, et al. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Journal of Infection 2005; 51: 294–298.
34.Allwinn, R, et al. Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity? European Journal of Clinical Microbiology & Infectious Diseases 2011; 30: 1223–1228.
35.Jokinen, S, et al. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. Journal of Infectious Diseases 2007; 196: 861–867.
36.Vandermeulen, C, et al. Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination. Journal of Infectious Diseases 2009; 199: 1457–1460.
37.Nardone, A, et al. Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets. Bulletin of the World Health Organization 2008; 86: 118–125.
39.Gidding, H. Australia's national serosurveillance program. NSW Public Health Bulletin 2003; 14: 90–93.
40.Kelly, H, et al. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002; 20: 3130–3136.